16, the FDA also approved the Intercept Blood System
for the preparation of plasma to reduce the risk of transfusion-transmitted infections.
INTERCEPT and the INTERCEPT Blood System
are trademarks of Cerus Corporation.
In addition, the INTERCEPT Blood System
provides enhanced patient safety by reducing the risk of transfusion-transmitted diseases through blood transfusions.
The approval of devices like the Intercept Blood System
allows blood establishments to prepare plasma that carries a lower risk of transmitting infectious pathogens through transfusion, said Karen Midthun, M.
Cerus now has exclusive rights to the INTERCEPT Blood System
for all three commonly transfused components: platelets, plasma and red blood cells, excluding rights in certain Asian countries for platelets and plasma.
benefiting from our many years of experience in Europe commercializing the INTERCEPT Blood System
and working with INTERCEPT plasma customers.
To date, the INTERCEPT Blood System
is the only technology approved in Switzerland for pathogen inactivation treatment of platelet and plasma components on a single platform.
The in-vitro study measured the inactivation level of the INTERCEPT Blood System
against a lipid-enveloped, single-stranded RNA virus of the coronavirus family.
The results were a determining factor in the INTERCEPT Blood System
for platelets receiving European regulatory approval last year, making it the only pathogen inactivation system for platelets approved and available for use in Europe.
Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the timing of the review process by the MCC, the potential approval and potential future launch of the INTERCEPT Blood System
for platelets in South Africa, and the potential benefits of the INTERCEPT Blood System
to safeguard patients from transfusion-transmitted infections.
Cerus Corporation (NASDAQ: CERS) announced today that Hemakim, Cerus' distributor for Turkey, has signed an agreement with the Florence Nightingale Hospital, a leading medical center in Turkey, to supply the INTERCEPT Blood System
for platelets and plasma.
Cerus Corporation (NASDAQ: CERS) announced today that it has signed a two-year agreement with the General Hospital of Vienna (AKH) to supply the INTERCEPT Blood System
Cerus Corporation (NASDAQ: CERS) announced today that Russia's Federal Medical-Biological Agency (FMBA) has awarded contracts for the purchase of 19 INTERCEPT Blood System
illumination devices for blood centers throughout the country.
22 /PRNewswire/ -- Blood Systems
intends to purchase up to 23 Sysmex XE-2100D(TM) Automated Hematology Analyzers for the organization's 21 component production/quality control laboratories across the United States, said Blood Systems
Vice President for Manufacturing Systems Dennis Harpool.
In addition, the company is conducting clinical trials of the Intercept Blood Systems
in the United States: a Phase III trial for platelets, a Phase III trial for plasma and a Phase Ic trial for red blood cells.